[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"old-age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:old-age":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,75,102,132,153,176,205,242,273,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100638705","inspiring-seniors-towards-exercise-promotion---2-100638705",false,"NCT07629739","Inspiring Seniors Towards Exercise Promotion - 2","iSTEP-2","Inclusion Criteria:\n\n* Adults over 65 years old.\n* Ambulatory without pain or the use of assisted walking devices.\n* Able to speak and read English.\n* Healthy enough to exercise at moderate intensity with or without medical clearance by a primary care physician.\n* Living in the community for the duration of the study (9-10 months).\n* Having a reliable means of transportation.\n* Having a safe place at home or at a residential area (at least 6 feet by 6 feet of open space) for unsupervised exercise training.\n* Being low-active (\\\u003C 90 min\u002Fweek of MAT and \\\u003C 2 days\u002Fweek of ST for the last 3 months).\n\nExclusion Criteria:\n\n* Concurrent diagnosis of neurological disorder (e.g., dementia, Parkinson's disease, multiple sclerosis, etc.), determined by self-report on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).\n* Known exercise contraindications (uncontrolled hypertension, joint problems, diabetes, metabolic conditions, etc.), determined by self-report on the PAR-Q+.\n* Current or upcoming cancer treatment, determined by self-report on the PAR-Q+.\n* Stroke or neural impairment in the past 6 months, as self-reported on the PAR-Q+.\n* Hip\u002Fknee\u002Fspinal fracture or surgery in the past 6 months, determined by self-report on the ACSM Health Screening Questionnaire.\n* Unable or unwilling to attend intervention classes, as determined by phone screening.\n* Currently participating in any other exercise or fitness-related research study, determined by phone screening.\n* Use of medications for cognitive impairment, as self-reported on the medication survey.\n* Change in dosage of medications prescribed for anxiety or depression within the previous 6 months, determined by self-report on a medication form.\n* Self-report regularly drinking \\> 14 alcoholic beverages a week or current illicit drug use, determined by self-report to screening surveys.\n* Cannot ambulate without a walker\u002Fcane, assessed in the American College of Sports Medicine (ACSM) Health Screening Questionnaire\n\n  • Having cognitive impairment, determined by the Montreal Cognitive Assessment (MoCA) BLIND \\\u003C 17.\n* Meet the threshold for clinical depression, determined by the Center for Epidemiological Studies Depression Scale Revised (CESD-R).\n* Uncorrected hearing or visual impairments, self-reported on the Health History Questionnaire.\n* Unable to understand the study procedure.\n* One of the household members is participating in this study, as self-reported during phone screening.",true,"ALL","65 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Older adults' low adherence to the national physical activity guidelines may stem from a failure to increase positive affective responses to exercise (e.g., enjoyment). Exercising with personalized, tempo-synchronous music playlists has shown promising effects on physical activity promotion in midlife-to-older adults during a cardiac rehab program. The purpose of this study is to determine how personalized, tempo-synchronous music playlists called rhythmic auditory stimulation (RAS) influence exercise behavior change and affective responses to exercise over 8 months among community-dwelling, sedentary older adults.",[27],"Old Age",[29,30,31,32],"Physical Activity","Exercise","Music","Cognitive decline prevention","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2026-05-26",{"date":41,"type":21},"2028-08",{"name":43,"class":44},"Emory University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100573877","phase-4-neurocognitive-function-changes-with-extended-release-tacrolimus-among-older-kidney-transplant-recipients-100573877","NCT06751992","Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients","Neuro-KTR","Inclusion Criteria:\n\n* Able to give informed consent for participation in the study\n* Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center\n* ≥1 year since the latest kidney transplantation\n* On IR tacrolimus as maintenance therapy\n* At a stable therapeutic tacrolimus level (5-10 ng\u002Fml) over the last ≥3 months\n* Stable kidney function \\[\\\u003C20% variability between the last two estimated glomerular filtration rate (eGFR)\\]\n* Utilizing English or Spanish as the primary language\n\nExclusion Criteria:\n\n* Dual organ transplantation\n* Rejection within the last three months\n* History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19)\n* History of Parkinson's disease\n* Decompensated liver disease\n* Active cancer\n* Uncontrolled depression or anxiety\n* Blindness\n* Deafness\n* Intellectual disabilities\n* Pregnancy\n* eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m2 at the time of enrollment\n* Total bilirubin \\>3.0 mg\u002FdL",{"count":55,"type":21},92,[57],"PHASE4","The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).",[60,27],"Kidney Transplant Recipients",[62,63,64,65,66],"Neurocognitive function","Tacrolimus","Kidney transplant recipients","Tremor","Insomnia",{"date":68,"type":37},"2026-05-28",{"date":70,"type":37},"2026-03-17",{"date":72,"type":21},"2027-10-01",{"name":74,"class":44},"Massachusetts General Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100582804","study-on-blood-pressure-variability-and-frailty-in-the-older-people-100582804","NCT06868069","Study on Blood Pressure Variability and Frailty in the Older People","Study on Blood Pressure Variability and Frailty in the Older People: the HypoPHrail Study","HypoPHrail","Inclusion Criteria:\n\n* Age ≥ 75 years\n* Diagnosis of hypertension according to the criteria of the European Society of Cardiology guidelines \\[Williams 2018\\]\n* Consent of the patient (or legal representative) to participate in the study\n\nExclusion Criteria:\n\n* Refusal of the patient or his\u002Fher legal representative\n* Life expectancy of less than 6 months","75 Years",{"count":85,"type":21},220,"OBSERVATIONAL","Observational prospective single-center, non-profit study. Primary objective of the study: To determine if the hypotensive phenotype, defined as one episode of daytime systolic blood pressure (SBP) \\\u003C90 mmHg (or two episodes of daytime SBP \\\u003C90 mmHg, if mean 24 h SBP is \\\u003C125 mmHg) detected at Ambulatory Blood Pressure Monitoring (ABPM) is associated with adverse events at follow up (death, hospitalization, falls, emergency room admission for uncontrolled hypertension, major cardiovascular events)",[89,27],"Hypertension",[91,92],"Blood pressure variability","Frailty","2026-03-25",{"date":95,"type":37},"2026-03-30",{"date":97,"type":37},"2024-07-15",{"date":99,"type":21},"2027-07-15",{"name":101,"class":44},"Istituto Auxologico Italiano",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":16,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100628232","guangzhou-community-elderly-fall-prevention-appropriate-technology-promotion-project-100628232","NCT07458958","Guangzhou Community Elderly Fall Prevention Appropriate Technology Promotion Project","Inclusion Criteria:\n\n* Between 60 and 80 years old (inclusive).\n* Community-dwelling.\n* Planning to reside at the current address for the next 12 months.\n* Able to walk 50 meters unaided (can use a cane).\n* Experienced one or more falls in the past 2 years, OR Is \"very worried\" or \"somewhat worried\" about falling (even without a fall history).\n* Willing to participate in the 12-month fall prevention program and follow-up assessments.\n* Possesses basic literacy skills (equivalent to elementary school level or above) and is capable of normal communication with the investigators, as judged by the staff.\n* In a stable health condition to participate, as determined by the investigator.\n\nExclusion Criteria:\n\n* Having an acute disease or an acute episode of a chronic disease.\n* Having hearing, vision, or cognitive impairments, or self-reported neurological or psychiatric diseases (e.g., epilepsy, dementia) that prevent normal communication and learning.\n* Self-reported serious diseases (e.g., cardiac, cerebral, renal, hepatic, respiratory, or hematologic systems) and judged by a doctor or on-site assessor as intolerant to physical activity.\n* Diagnosed with conditions that explicitly affect balance function (e.g., vestibular disorders, cerebellar system lesions, vertigo, Ménière's disease).\n* Requires a wheelchair or assistance from another person to walk.\n* Likely to move away from the current residence or be absent for an extended period within the next 6 months.\n* Unwilling to accept the 12-month follow-up.","60 Years","80 Years",{"count":111,"type":21},320,[24],"This Guangzhou-based project uses a randomized controlled trial to test home environment modifications (e.g., anti-slip mats, lighting) for preventing falls among 320 community-dwelling elders. Over 12 months, it assesses effectiveness, cost-efficiency, and scalability, with rigorous quality control and multi-level stakeholder collaboration.",[115,27],"Fall",[117,118,119,120,121],"Cost-Effectiveness Analysis","Home Hazard Assessment and Modification","RCT","Community-Dwelling Older Adults","Fall Prevention","2026-03-19",{"date":124,"type":37},"2026-03-23",{"date":126,"type":37},"2026-01-01",{"date":128,"type":21},"2027-02-01",{"name":130,"class":131},"Guangzhou Center for Disease Control and Prevention","OTHER_GOV",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100623682","cdk46-inhibitors-in-breast-cancer-elderly-patients-an-observational-ambispective-longitudinal-multicenter-study-100623682","NCT07399808","CDK4\u002F6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study","Inclusion Criteria:\n\n* age over 18 years\n* patients with solid tumours undergoing active systemic treatment with CDK4\u002F6 for adjuvant disease\n\nExclusion Criteria:\n\n* Patients who are unable to understand informed consent document","18 Years",{"count":140,"type":21},100,"Breast cancer is one of the tumors with the highest incidence and current evidence indicates a higher prevalence in elderly patients (≥70 years) with a higher mortality rate due to immunosenescence, diagnostic delay and under treatment. Elderly patients are still poorly represented in clinical trials and the main indications for the treatment of the elderly population are extrapolated from the guidelines used in studies conducted predominantly on the younger population. In particular, these guidelines do not take into account the significant variability of elderly patients, in particular their comorbidities, performance status, physiological age and frailty.\n\nThe aim of this study is to improve understanding of the clinical efficacy and safety of CDK 4\u002F6i in older women in a real-world setting compared to younger women.",[143,27],"Breast Cancer","2026-02-05",{"date":146,"type":37},"2026-02-10",{"date":148,"type":37},"2025-03-21",{"date":150,"type":21},"2026-12",{"name":152,"class":44},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100612361","relationships-between-sexuality-and-mental-health-in-older-people-100612361","NCT07252583","Relationships Between Sexuality and Mental Health in Older People","PASS","Inclusion Criteria:\n\n* Voluntary participant aged ≥ 60 years (male or female)\n\nExclusion Criteria:\n\n* Inability to understand or communicate in French\n* Major neurocognitive disorders\n* Refusal to participate in the study",{"count":161,"type":21},200,[24],"The prevalence of sexual activity decreases with age, particularly among individuals over 60 years old. Although physical dysfunctions, such as erectile disorders, play a role, the decline in sexuality is also linked to cultural and social factors, such as stereotypes and the loss of a partner. Sexuality in adulthood impacts both mental and physical health, contributing to better quality of life and reduced risks of cardiovascular disease and cancer. Maintaining a fulfilling sexual life among older adults is a public health issue that remains underexplored, particularly regarding its relationship with mental health.\n\nPrimary objective To explore the association between sexuality and mental health in community-dwelling older adults.\n\nSecondary objectives To study the relationships between the different dimensions of the questionnaires (ISS, QLQC30, HAD) To examine the association between sexuality and psychotropic drug use To compare sexuality and mental health among older adults belonging to senior associations and those living in independent residences",[27],[166],"sexuality","2025-11-24",{"date":169,"type":37},"2025-11-26",{"date":171,"type":37},"2025-10-01",{"date":173,"type":21},"2026-09",{"name":175,"class":44},"University Hospital, Clermont-Ferrand",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100512299","phase-4-mini-dose-dexmedetomidine-esketamine-infusion-and-perioperative-sleep-quality-100512299","NCT05950646","Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality","Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥65 years and \\\u003C90 years;\n* Scheduled to undergo unilateral knee or hip arthroplasty.\n\nExclusion Criteria:\n\n* Refuse to participate;\n* Hypnotic therapy for sleep disorders within 3 months;\n* Preoperative history of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n* Diagnosed as obstructive sleep apnea, or at high risk of moderate to severe obstructive sleep apnea according to the Stop-Bang questionnaire;\n* Inability to communicate in the preoperative period because of coma, profound dementia, or language barrier;\n* Sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C50 beats\u002Fmin), or atrioventricular block above grade II without pacemaker implanted;\n* Severe hepatic dysfunction (Child-Pugh class C), renal dysfunction (required preoperative dialysis), or expected survival ≤24 hours;\n* Receiving treatment with dexmedetomidine, clonidine, or esketamine;\n* Allergy to dexmedetomidine or esketamine.","90 Years",{"count":185,"type":21},154,[57],"Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine combined infusion at night can improve perioperative sleep quality in patients scheduled for knee or hip replacement surgery.",[27,189,190,191,192,193],"Knee Replacement Surgery","Hip Replacement Surgery","Dexmedetomidine","Esketamine","Sleep Quality",[27,189,190,191,192,193],"2025-07-29",{"date":197,"type":37},"2025-07-30",{"date":199,"type":37},"2023-11-01",{"date":201,"type":21},"2025-12",{"name":203,"class":44},"Peking University First Hospital",2,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":45},"100394496","integrating-health-promotion-with-and-for-older-people---ehealth-100394496","NCT04416815","Integrating Health Promotion With and for Older People - eHealth","Integrating Health Promotion With and for Older People - eHealth: a Randomised Controlled Trial, in the Context of Good Quality Local Health Care","IHOPe","Inclusion Criteria:\n\n* National registration within the Västra Götalands region (VGR), community dwelling people (men and women) aged 75 and older living in ordinary housing, and screened as frail at a primary care center or the emergency department but not hospitalized.\n\nExclusion Criteria:\n\n* In need of palliative care in the final stages of life, no registered address, participating in any other conflicting randomised study, or cognitive dysfunctional (not oriented to time, place and person).",{"count":85,"type":21},[24],"The Integrating Health promotion with and for Older People eHealth (IHOPe) project is expected to contribute vital knowledge on how older peoples capabilities and societal resources can be used in a more efficient way to promote health, self-management and enhance teamwork in partnership.The aim is to describe and evaluate this person-centered e-support intervention that promotes a sustainable partnership between community-dwelling frail older people and health and social care professionals. A digital platform, co-created with users and designed to create inclusion of individuals who today are living in a digital alienation, will be used in the health planning. In IHOPe frail older people will be able to identify their potential health issues but also their resources together with team partners from health- and social care, family or societal representatives. The intervention consists of person-centered phone calls with a health care professional as well as access to a digital platform that is accessible to the old person and invited team-partners. The project includes a randomized controlled trial, a process evaluation and a health economic evaluation. People 75 years or older screened as frail will be included. Also, in the process evaluation team-partners using the digital platform will be included. Specifically, this project is expected to reduce hospitalizations, result in improved or retained self-efficacy whilst being cost effective. Additionally, the project is expected to enhance frail older peoples opportunities to participate as an equal partner in their contacts with health and social services.",[92,27],[218,219,119,220,221,222,223,224,92,225,226,227,228,229,230,231,232],"Person-centredness","Telemedicine","e-health","Process Evaluation","Health Economic Evaluation","Health Plan","Partnership","Elderly","Person-centred care","Patient-centred care","Person-centered care","Patient-centered care","Integrated care","Health promotion","eHealth","2025-03-11",{"date":235,"type":37},"2025-03-12",{"date":237,"type":37},"2021-01-25",{"date":239,"type":21},"2027-12-31",{"name":241,"class":44},"Göteborg University",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":254,"conditions":255,"keywords":259,"overallStatus":263,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100575229","phase-2-reduced-dose-conditioning-regimen-containing-tbi-in-hsct-treating-elderly-patients-with-aplastic-anemia-100575229","NCT06769568","Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia","The Safety and Efficacy of Reduced-dose Conditioning Regimen Containing TBI in Hematopoietic Stem Cell Transplantation Treating Elderly Patients With Aplastic Anemia","Inclusion Criteria:\n\n* ( 1 ) Diagnosis of aplastic anemia, including very severe aplastic anemia, severe aplastic anemia, chronic aplastic anemia and hepatitis-associated aplastic anemia.\n\n( 2 ) Age older than or equal to 50 years old. ( 3 ) Informed consent can be signed by themselves. ( 4 ) HIV negative, HBV, HCV negative. ( 5 ) Informed consent must be signed before the start of the study procedure. Informed consent must be signed by the patient or immediate family members who are 18 years old or older. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.\n\nExclusion Criteria:\n\n* ( 1 ) Patients who underwent more than one time of transplantation before enrollment ; ( 2 ) Uncontrolled infection, mechanical ventilation or hemodynamic instability at the time of enrollment ; ( 3 ) Diagnosis of clinically significant severe liver dysfunction ( defined as Child-Pugh C grade ) within 5 days before enrollment ; or within 5 days before enrollment, AST or ALT was 5 times higher than the upper limit of normal, or serum total bilirubin was 2 times higher than the upper limit of normal ; ( 4 ) End-stage renal insufficiency was diagnosed within 5 days before enrollment, and creatinine clearance rate was less than 10ML \u002F min.\n\n( 5 ) Simultaneous diagnosis of moderate hepatic insufficiency and moderate renal insufficiency ( moderate hepatic insufficiency was defined as Child-Pugh B grade ; moderate renal insufficiency was defined as creatinine clearance rate less than 50ML \u002F min ).\n\n( 6 ) In addition to localized basal cell or squamous cell skin cancer or treatment conditions ( such as lymphoma ), there are active solid tumor malignant tumors.\n\n( 7 ) There was active HIV replication before enrollment. HCV antibody positive, HCV-RNA positive, or HBsAg positive could be detected within 90 days before enrollment. The serological response to HIV or active hepatitis C virus is known to be positive.\n\n( 8 ) Having a mental illness or other condition that does not cooperate with the requirements of research, treatment and monitoring.\n\n( 9 ) unable or unwilling to sign the consent form. ( 10 ) Patients with other special conditions who were assessed as unqualified by the researchers.","50 Years",{"count":251,"type":21},20,[253],"PHASE2","The TBI-containing reduced-dose conditioning regimen was used to treat elderly patients with aplastic anemia who received hematopoietic stem cell transplantation. The overall survival rate, GVHD-free survival rate, all-cause mortality,et al were studied. The modified conditioning regimen included TBI 2Gy, -7d, busulfan 3.2mg \u002F kg-6d ; fludarabine 30mg \u002F m2 \u002F d-5 \\~ -1d ; cyclophosphamide 25-30mg \u002F kg \u002F d-5 \\~ -2d ; ATG ( rabbit ) 2 mg \u002F kg \u002F d-5 \\~ -1d.",[256,257,258,27],"Aplastic Anaemia","HSCT","TBI",[260,257,261,262],"aplastic anemia","old age","conditioning regimen","NOT_YET_RECRUITING","2025-01-07",{"date":266,"type":37},"2025-01-10",{"date":268,"type":21},"2025-01-31",{"date":270,"type":21},"2028-09-30",{"name":272,"class":44},"Institute of Hematology & Blood Diseases Hospital, China",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":263,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100567446","clinical-study-of-g-protein-biased----opioid-receptor-agonist-oliceridine-for-optimizing-postoperative-analgesia-under-general-anesthesia-100567446","NCT06668298","Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia","Inclusion Criteria:\n\n1. Age\\>65 years old\n2. ASA Level I-III\n3. BMI 18.5-29.9\n4. Patients undergoing knee joint surface replacement surgery under general anesthesia\n5. Postoperative Patient Controlled Intravenous Analgesia Pump (PCIA) Treatment\n6. Possess reading and writing abilities\n7. You can sign an informed consent form\n\nExclusion Criteria:\n\n1. Suffering from chronic pain or mental illness before surgery\n2. Unable to communicate due to cognitive impairment or language barriers before surgery\n3. Patients who have used opioid drugs three days before surgery\n4. Patients with long-term alcohol consumption\n5. Abnormal liver and kidney function or dialysis patients\n6. Concurrent severe cardiovascular, respiratory, and autonomic neuropathy\n7. Participated in clinical studies of other drugs or medical devices in the past 3 months",{"count":20,"type":21},[24],"Traditional opioid analgesia is a treatment method for moderate to severe pain. However, the use of opioid drugs is not without risks. When treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. The purpose of this study is to evaluate the comparison of G protein biased μ - opioid receptor agonist oliceridine and traditional μ - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.",[27],[261,284,285],"knee arthroplasty","pain","2024-10-30",{"date":288,"type":37},"2024-10-31",{"date":290,"type":21},"2024-11",{"date":292,"type":21},"2025-06",{"name":294,"class":44},"Henan Provincial People's Hospital",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":45},"100422613","neuromodulation-in-the-elderly-depressed-a-brain-imaging-pilot-study-100422613","NCT04783103","Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study","Neuromodulation in the Elderly Depressed: a Brain Im-aging Pilot Study","Inclusion Criteria:\n\n* • In- and outpatients (age 65 year or older).\n\n  * Meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM 5) criteria for unipolar depression according 17-item Hamilton depression rating scale (HDRS-17) score of 17 or more.\n  * Failed to respond to at least one adequate course with an antidepressant medication trial, including the current one.\n  * Intention to continue the current (\\>6 weeks) antidepressant treatment at a stable dose dur-ing the stimulation.\n  * Benzodiazepines are permitted up to a maximum dose of 40 mg diazepam or equivalent. If the dosage has been recently changed, it should be stable for at least 2 weeks.\n  * Able to read, understand and sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* • Psychosis (except depression with psychotic features).\n\n  * A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, substance abuse, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) with the exception of dental fillings. The presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with the following neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with (study related) MRI.\n  * Patients with cognitive disturbances or dementia (Mini Mental State) \\\u003C 24.\n  * Suicide attempt within 6 months before the start of the study or present high risk of suicide per the investigator's clinical judgment and indicative response\\* on the Columbia-Suicide Severity Rating Scale (C-SSRS) and 21-items Beck Scale for Suicide Ideation (BSI). \\*'yes' on Item 5 (active suicidal ideation with specific plan and intent).\n  * Any change in the habitual psychopharmacological agents will be considered as dropout.",{"count":303,"type":21},44,[24],"To evaluate safety and efficacy of an accelerated deep brain Transcranial Magnetic stimulation (adTMS) and transcutaneous direct current stimulation (tDCS) protocol in an elderly depressed patient population",[27,307],"Depressive Disorder, Treatment-Resistant","2022-11-02",{"date":310,"type":37},"2022-11-03",{"date":312,"type":37},"2021-05-07",{"date":314,"type":21},"2026-07",{"name":316,"class":44},"Universitair Ziekenhuis Brussel"]